WO2005007194A1 - Formulaciones mucoadhesivas semisólidas - Google Patents
Formulaciones mucoadhesivas semisólidas Download PDFInfo
- Publication number
- WO2005007194A1 WO2005007194A1 PCT/ES2004/000336 ES2004000336W WO2005007194A1 WO 2005007194 A1 WO2005007194 A1 WO 2005007194A1 ES 2004000336 W ES2004000336 W ES 2004000336W WO 2005007194 A1 WO2005007194 A1 WO 2005007194A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- formulation according
- agent
- carbopol
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Definitions
- bioadhesion is used to define the ability of a natural or synthetic material to stick to biological membranes, resulting in an intimate contact of the material with the tissue for a more or less prolonged period of time.
- Mucoadhesion refers to a special case of bioadhesion in which the tissue is a mucosa.
- the administration of drugs vaginally may be a preferred alternative in certain cases although, for the therapy to be successful, some difficulties must be overcome.
- the formulations to be used in this way must be carefully designed so as not to produce unwanted effects on the patient that lead to non-compliance with the treatment. It has been seen that tablets and suppositories can cause discomfort (irritation), ovules and creams can cause excessive vaginal discharge.
- the compositions possess good bioadhesive properties because, due to the anatomical and physiological characteristics of the vagina, it is very difficult to achieve that they remain attached to its walls and can release the drug in this area for a prolonged period of time.
- EP 0431719, EP 0500807, EP 0719146, WO 96/10989, WO 99/13862 and WO 01/24788 describe bioadhesive formulations with a crosslinked carboxylic acid polymer (Polycarbophil) and a gelling polymer (preferably Carbopol 934P) which may contain Different active ingredients
- a crosslinked carboxylic acid polymer Polycarbophil
- a gelling polymer preferably Carbopol 934P
- the documents FR 2609391 and GB 2199495 describe bioadhesive suppositories for vaginal application formed by at least one hydrophilic polymer (NaCMC, HPMC or Carbopol) and a medicament (anti-fungals of the nystatin or imidazole type).
- WO 85/02092 describes bioadhesive compositions for application in skin or mucous membranes that include a carboxy-functional crosslinked polymer (Polycarbophil) and a therapeutic agent.
- US 5942243 describes a hydrogel-shaped mucoadhesive composition comprising one or more drugs (clotrimazole, nonoxynol-9, progesterone, etc.) and a thermoplastic copolymer.
- EP 0818194 describes biomembrane adhesive moisturizing compositions preferably comprising a polymer crosslinked with carboxyl groups (Stablese, Carbopol 934P), a water soluble polymer (Gantrez, NaCMC) and a compound polyhydroxylated (glycerin, propylene glycol).
- WO 98/05303 describes polycarbophil and antifungal or antiprotozoal mucoadhesive complexes (of the imidazole or triazole type) useful in the topical treatment of mucosal conditions, and gel formulations containing them.
- WO 00/47144 describes a vaginal bioadhesive composition based on synergistic formulation of carrageenan, agarose, polymers of acrylic acid (Pemulen) or Polycarbophil and therapeutic agent.
- WO 00/50078 describes microspheres for application in mucous membranes comprising at least one antigen and one bioadhesive (HPMC, Carbopol, Polycarbophil).
- the vagina is a hollow fibromuscular tube formed by three tissue layers: mucosa, muscle and adventitia.
- the vaginal mucosa is constituted by stratified squamous epithelium not keratinized, lacking glands.
- the vaginal epithelium is hormone sensitive and manifests cyclic and age-dependent changes, both morphological and functional. Until puberty a physiological atrophy occurs.
- vulvovaginitis Inflammatory conditions that affect the vaginal mucosa and may also affect the vulva are called vulvovaginitis. They can be secondary to multiple causes including infections, irritation, allergy or systemic diseases. For the symptomatic relief of extreme vaginal itching, especially in pediatric vulvovaginitis, adrenocorticoid derivatives are usually used topically (in skin or external mucous membranes). Vulvovaginal infections require treatment with different drugs orally or intravaginally, for example antiseptics, antibiotics, antifungals or antivirals, depending on their etiology.
- prostaglandins or their analogues In induction of labor or termination of pregnancy, it is contemplated to administer prostaglandins or their analogues, with a view to maturation and dilation of the uterine cervix and uterine stimulation.
- scar diseases for example after postpartum episiotomy or after cervical conization, drugs that promote healing are usually administered topically.
- contraceptive methods the administration of gestagens and estrogens has been proposed vaginally.
- a first aspect of the present invention relates to semi-solid mucoadhesive formulations comprising at least: - a first bioadhesive gelling polymer of the polyacrylic acid type crosslinked with divinylglycol in an amount between 0.1% and 5% by weight of the formulation , - a second bioadhesive gelling polymer derived from acrylic acid crosslinked with allyl sucrose or allyl pentaerythritol, in an amount between 0.1% and 5% by weight of the formulation, - a moisturizing / wetting agent in an amount between 0% and 20% in formulation weight, - a fatty / lipophilic component, in an amount between 0% and 50% by weight of the formulation, - a solubilizing / emulsifying agent in an amount between 0% and 70% by weight of the formulation, - agent Neutralizer in sufficient quantity to place the pH of the formulation between 2 and 6, - a pharmacologically active agent, - water, in sufficient quantity
- the combination of polymers of the present invention makes the resulting mucoadhesive gels show great versatility.
- they allow incorporating very different amounts of drug (from hundredths to tens of grams of active ingredient / 100 grams of formulation) maintaining excellent bioadhesion and achieving prophylactic or therapeutic efficacy.
- the qualitative and quantitative selection of the components of the mucoadhesive formulations of the present invention allows to adjust the cession profile of the drug to the prophylactic and / or therapeutic objective sought in each case, making it possible to space the applications (up to a daily application or even more) and / or obtain a safe product.
- Fig.l graph illustrating the "in vitro" bioadhesion (indicated in terms of area) of five formulations (A, B, C, D and E) according to the present invention.
- Fig. 2 - graph illustrating "in vitro" bioadhesion compared to two formulations according to the present invention (G and H) with a commercially available one (F).
- Fig. 3 - graph illustrating the "in vivo" bioadhesion of a 0.005% estriol formulation to the vaginal mucosa of ovariectomized rats.
- FIG. 4 - graph illustrating the "in vivo" bioadhesion of a 0.005% estriol formulation to the vaginal mucosa of unvariectomized rats.
- Fig. 5 illustrating the "in vitro" assignment profiles of four formulations (K, L, Q, R) according to the present invention.
- Fig. 6 illustrating the "in vitro” assignment profiles of six 0.05% estriol formulations with different excipients (J, K, M, N, O, P).
- An embodiment of the present invention relates to semi-solid mucoadhesive formulations comprising at least: - a first bioadhesive gelling polymer of the polyacrylic acid type crosslinked with divinylglycol, in particular Polycarbophil AAl, in an amount between 0.1% and 5% by weight of the formulation, - a second bioadhesive gelling polymer derived from acrylic acid cross-linked with allyl sucrose or allyl pentaerythritol, in particular Carbopol 971P, in an amount between 0.1% and 5% by weight of the formulation, - a moisturizing / wetting agent selected from the group consisting of glycerin, propylene glycol, dipropylene glycol, polyethylene glycols (for example PEG-4, PEG-6,
- polyoxyethylene sorbitan fatty acid esters for example Polysorbates 60 and 80
- sodium alkyl sulfates such as sodium lauryl sulfate
- sorbitan esters glyceryl monostearate
- polyoxyethylene alkyl ethers polyoxyethylene stearates
- a neutralizing agent selected from the group consisting of aqueous solutions of NaOH, KOH and triethanolamine, in an amount sufficient to place the pH of the formulation between 2 and 6, - a pharmacologically active agent, - water, in sufficient quantity to complete the formulation.
- Polycarbophil AAl is used in an amount between 0.5% and 2.5%, and more preferably between 0.75% and 1.5%
- Carbopol 971P is used in an amount between 0.1 % and 1%, and more preferably between 0.25% and 0.5% by weight of the formulation.
- a moisturizing agent it will preferably be in an amount between 5% and 15% by weight of the formulation.
- a fatty and / or solubilizing compound it will preferably be in an amount between 5% and 50%, and more preferably between 10% and 40% by weight of the formulation. If it is necessary to include, in addition, an emulsifying agent this will preferably be in an amount between 0.1% and 15% by weight of the formulation.
- Antiprotozoals metronidazole Antibacterials: clindamycin, trimethoprim, sulfamethoxazole, penicillins (ampicillin, methicillin), cephalosporins, tetracyclines (doxycycline), bacitracin, lincomycin, colistin, polymyxin B, vancomycin, gentamicin, kanamycin, neomycin, streptomycin, icina erythro, amikacin, tobramycin .
- Anti-inflammatory corticosteroids beta-metasona, hydrocortisone, triamcinolone, mometasone.
- Nonsteroidal anti-inflammatory drugs diclofenac, etodolac, ibuprofen, mdomethacin, meloxicam, piroxicam.
- Smooth muscle relaxants ⁇ -adrenergic agonists: terbutalma, ritodrma, isoxsuprma, fenoterol, salambutol, hexoprenalma, metaproterenol, bitolterol and pirbuterol.
- compositions are useful in the treatment or prevention of urogenital atrophy due to estrogen deficiency.
- bioadhesive formulations comprising clotrimazole between 1 and 50% by weight of the formulation. These compositions are useful in the treatment or prevention of vaginal candidiasis.
- mucoadhesive formulations containing clindamyme between 1 and 30% by weight of the formulation. These compositions are useful in the treatment or prevention of vagmosis by infectious agents.
- the mucoadhesive compositions of the invention can be applied in an amount sufficient to form a layer over the entire vaginal surface, usually between 1 to 5 grams, which allows an effective and safe dosage regimen to be obtained.
- the rest of the components can be incorporated before forming the gel.
- the fat-soluble active ingredients can be dissolved or dispersed in the moisturizing / wetting agent before being incorporated into the gel.
- Another method that can be used to obtain the mucoadhesive formulations of the present invention comprises the steps of: 1'-dissolving the preservatives in distilled water, adding an acidifying agent until obtaining a suitable pH so that the polymers do not gel in the next stage, 2'- add the gelling polymers to the solution of the previous step, stirring vigorously until a perfect dispersion is achieved, 3'- incorporate the active agent into the mixture consisting of the fatty / lipophilic component and the solubilizing / emulsifying agent, 4'- add the mixture of stage 2 'to the dispersion of stage 1', 5'- add the neutralizing agent until the appropriate pH is achieved for the gelation of the polymers and for the vaginal application.
- any other method known to a person skilled in the art may be used to prepare the formulations of the present invention.
- Formulation A Clotrimazole 25% (w / w) Carbopol 971P 0.5% Polycarbophil AA- -1 1.5% Glycerin 10% NaOH csp pH 4.5 Water csp 100%
- Formulation B Progesterone 25% (w / w) Carbopol 971P 0.5% Polycarbophil AA- -1 1.5% Propylene Glycol 10% Cremophor 10% NaOH csp pH 4.5 Water csp 100%
- Formulation C Progesterone 25% (w / w) Carbopol 971P 0.5% Polycarbophil AA - -1 1.5% Propylene glycol 10% NaOH csp pH 4.5 Water csp 100%
- Formulation D Estriol 0.05% (w / w) Carbopol 971P 0.5% Polycarbophil AA- • 1 1.5% Glycerin 10 % Cremophor 10% NaOH csp pH
- Wistar females 20 ovariectomized and 20 without ovariectomized.
- the 20 operated rats were randomly distributed in 4 groups with
- Group 1A ovariectomized rats, smear performed at 1, 8 and 15 hours
- Group 2A ovariectomized rats, smear performed at 2, 10 and 18 hours
- Group 3A ovariectomized rats, smear performed at 4 , 11 and 21 hours
- Group 4A ovariectomized rats, smear performed at 6, 12 and 24 hours
- Group IB rats without ovariectomized, smear performed at 1, 8 and 15 hours
- Group 2B rats without ovariectomized, smear performed at 2 , 10 and 18 hours
- Group 3B rats without ovariectomizing, smear performed at 4, 11 and 21 hours
- Group 4B rats without ovariectomizing, smears performed at 6, 12 and 24 hours.
- a calibration line with fluorescence values for standard solutions (0.05-10 ⁇ g / ml) is made and used to obtain the estriol concentration of the different samples.
- the assignment profiles of the formulations J to R defined below were determined.
- Formulation J Estriol 0.05% (w / w) Carbopol 971P 0.5% Polycarbophil AA-1 1.0% Propylene glycol 10% NaOH csp pH 4.5 Water csp 100
- Formulation K Estriol 0.05% (p / p) Carbopol 971P 0.5% Polycarbophil AA-1 1.5% Glycerin 10% NaOH csp pH 4.5 Water csp 100
- Formulation L Same as Form.K but also contains 10% Cremophor.
- Formulation M Same as Form. K but also contains 5% Paraffin.
- Formulation N Same as Form. K but with 10% Propylene Glycol instead of 10% Glycerin Formulation O: Same as Form. K but also contains 5% Labrafil.
- the pharmaceutical formulations were administered topically, by means of a vaginal cannula, in a volume of 125 ⁇ L the first formulation and 250 ⁇ L the remaining three. After 15 days had elapsed since the ovariectomy, a daily vaginal smear was performed on each rat until the menopausal status was verified in all rats, determining the absence of cornified cells. On the same day that no cornified cells were detected, a sample of 0.1 mL of blood was extracted from each rat for the determination of baseline estriol levels by enzymatic immunoassay (EIA) (Oxford Biomedical Commercial Kit).
- EIA enzymatic immunoassay
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Adhesive Tapes (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/565,062 US8663688B2 (en) | 2003-07-16 | 2004-07-16 | Semi-solid mucoadhesive formulations |
SI200431522T SI1652535T1 (sl) | 2003-07-16 | 2004-07-16 | Poltrdni mukoadhezivni pripravki |
EP04742064A EP1652535B1 (en) | 2003-07-16 | 2004-07-16 | Semi-solid mucoadhesive formulations |
DE602004029369T DE602004029369D1 (de) | 2003-07-16 | 2004-07-16 | Halbfeste mukoadhäsive formulierungen |
PL04742064T PL1652535T3 (pl) | 2003-07-16 | 2004-07-16 | Półstałe formulacje mukoadhezyjne |
AT04742064T ATE482723T1 (de) | 2003-07-16 | 2004-07-16 | Halbfeste mukoadhäsive formulierungen |
JP2006519939A JP4891765B2 (ja) | 2003-07-16 | 2004-07-16 | 半固体粘膜接着製剤 |
DK04742064.1T DK1652535T3 (da) | 2003-07-16 | 2004-07-16 | Halvfaste slimhindefæstnende formuleringer |
HR20100635T HRP20100635T1 (hr) | 2003-07-16 | 2010-11-24 | Polučvrste mukoadhezivne formulacije |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200301672A ES2237298B1 (es) | 2003-07-16 | 2003-07-16 | Formulaciones mucoadhesivas semisolidas. |
ESP200301672 | 2003-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005007194A1 true WO2005007194A1 (es) | 2005-01-27 |
Family
ID=34072910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2004/000336 WO2005007194A1 (es) | 2003-07-16 | 2004-07-16 | Formulaciones mucoadhesivas semisólidas |
Country Status (13)
Country | Link |
---|---|
US (1) | US8663688B2 (es) |
EP (2) | EP2100612A3 (es) |
JP (1) | JP4891765B2 (es) |
AT (1) | ATE482723T1 (es) |
CY (1) | CY1110954T1 (es) |
DE (1) | DE602004029369D1 (es) |
DK (1) | DK1652535T3 (es) |
ES (2) | ES2237298B1 (es) |
HR (1) | HRP20100635T1 (es) |
PL (1) | PL1652535T3 (es) |
PT (1) | PT1652535E (es) |
SI (1) | SI1652535T1 (es) |
WO (1) | WO2005007194A1 (es) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006138715A1 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company, Inc. | Estrogen compositions for vaginal administration |
WO2006138735A2 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company, Inc. | Gel compositions for topical administration |
WO2006138686A1 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company, Inc. | Estrogen compositions for vaginal administration |
WO2007021805A2 (en) * | 2005-08-12 | 2007-02-22 | Drugtech Corporation | Estrogen compositions and therapeutic methods of use thereof |
JP2010531302A (ja) * | 2007-06-25 | 2010-09-24 | イタルファルマコ、ソシエダッド、アノニマ | エストリオールの低用量での使用 |
US8663688B2 (en) | 2003-07-16 | 2014-03-04 | Itf Research Pharma, S.L.U. | Semi-solid mucoadhesive formulations |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1667619A4 (en) | 2003-09-19 | 2007-10-10 | Drugtech Corp | PHARMACEUTICAL FEEDING SYSTEM |
CN101405006A (zh) * | 2006-01-20 | 2009-04-08 | 梨树医药公司 | 治疗萎缩性阴道炎的方法 |
DK2018164T3 (en) | 2006-05-12 | 2017-06-12 | Christian Noe | Use of combination preparations comprising antimycotics |
EP2034984A4 (en) * | 2006-06-02 | 2013-03-06 | Pear Tree Women S Health Care | PROCESS FOR TREATING ATROPHIC VAGINITIS |
WO2008005783A2 (en) * | 2006-06-30 | 2008-01-10 | Drugtech Corporation | Treatment of non- infectious inflammatory vulvovaginitis with a bioadhesive clindamycin composition |
ES2344673B1 (es) * | 2008-08-07 | 2011-05-03 | Italfarmaco, S.A. | Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral. |
CA2732626A1 (en) * | 2008-08-12 | 2010-02-18 | Novabay Pharmaceuticals, Inc. | Antimicrobial gel formulations |
BRPI0803568B8 (pt) * | 2008-08-14 | 2021-05-25 | Biolab San Us Farm Ltda | composição mucoaderente |
ES2344675B1 (es) * | 2008-12-19 | 2011-04-28 | Italfarmaco, S.A. | Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular. |
EA023396B1 (ru) * | 2010-04-01 | 2016-05-31 | Фарманест Аб | Термогелеобразующие композиции анестетиков |
CN102293735B (zh) * | 2011-08-19 | 2013-05-01 | 辽宁万嘉医药科技有限公司 | 一种抗真菌咪唑类药物缓释凝胶和制备方法 |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
CN102600288B (zh) * | 2012-04-20 | 2014-03-05 | 广西源安堂药业有限公司 | 一种治疗阴道炎的复方黄松凝胶药物及其制备方法 |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10045935B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
KR101358993B1 (ko) | 2012-09-05 | 2014-02-06 | 임혜선 | 네일 프린팅용 트랜스퍼 솔루션 및 이를 이용한 네일 프린팅 방법 |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
JP2017523138A (ja) | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 経皮クリーム |
US20160175271A1 (en) * | 2014-12-19 | 2016-06-23 | Gavis Pharmaceuticals | Rectal suppository for ulcerative colitis |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
ES2949053T3 (es) * | 2016-01-07 | 2023-09-25 | Viramal Ltd | Composiciones de gel para administración transdérmica para maximizar las concentraciones de fármaco en el estrato córneo y suero, y métodos de uso de las mismas |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
CN113164384A (zh) | 2018-10-26 | 2021-07-23 | 维拉莫有限公司 | 黏膜粘附性凝胶组合物 |
CN110151680A (zh) * | 2019-04-10 | 2019-08-23 | 重庆医药高等专科学校 | 雌三醇凝胶产品及制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028515A1 (en) * | 1999-10-22 | 2001-04-26 | Líf-Hlaup ehf. Bio-Gels Pharmaceuticals Inc. | Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
ES2173203T3 (es) * | 1994-10-07 | 2002-10-16 | Columbia Lab Bermuda Ltd | Composicion que comprende una formulacion que actua contra las enfermedades sexualmente transmisibles y su utilizacion. |
WO2003037382A1 (en) * | 2001-10-29 | 2003-05-08 | Columbia Laboratories (Bermuda) Limited | Low concentration of peroxide for treating or preventing vaginal infections |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4615697A (en) | 1983-11-14 | 1986-10-07 | Bio-Mimetics, Inc. | Bioadhesive compositions and methods of treatment therewith |
NZ222698A (en) | 1987-01-08 | 1990-02-26 | Squibb & Sons Inc | Bioadhesive suppository formulations comprising a medicament, water, a hydrocolloid and low melting point base |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
DK0431719T3 (da) | 1989-10-31 | 1995-02-27 | Columbia Lab Inc | Vaginalt vævsbefugtende præparat |
DK0500807T3 (da) | 1989-10-31 | 2000-02-07 | Columbia Lab Inc | Præparat og fremgangsmåde til befugtning af væv |
US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
AT408067B (de) * | 1995-03-17 | 2001-08-27 | Gebro Pharma Gmbh | Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung |
US5741525A (en) | 1995-10-24 | 1998-04-21 | Marshall University Research Corporation | Vaginal pharmaceutical hydrogen peroxide composition |
AU714797B2 (en) | 1996-06-14 | 2000-01-13 | Mcneil-Ppc, Inc. | Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof |
IT1284874B1 (it) | 1996-08-02 | 1998-05-22 | Farmigea Spa | Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici |
US5942243A (en) | 1996-11-12 | 1999-08-24 | Polytherapeutics, Inc. | Mucoadhesive compositions for administration of biologically active agents to animal tissue |
AU729546B2 (en) | 1996-11-14 | 2001-02-01 | Lipomedica Ehf. | Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections |
DE69819748T2 (de) | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
US6159491A (en) | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
EP2275133A1 (en) | 1999-02-26 | 2011-01-19 | Novartis Vaccines and Diagnostics, Inc. | Use of bioadhesives and adjuvants for the mucosal delivery of antigens |
SE522260C2 (sv) | 1999-10-01 | 2004-01-27 | Ericsson Telefon Ab L M | Metod, system och säkerhetsadapter för att exekvera säker dataöverföring i ett trådlöst nät |
UA74168C2 (uk) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
ATE355854T1 (de) * | 2000-08-03 | 2007-03-15 | Antares Pharma Ipl Ag | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6967194B1 (en) * | 2002-09-18 | 2005-11-22 | Susan Matsuo | Bio-identical hormones and method of use |
ES2237298B1 (es) | 2003-07-16 | 2006-11-01 | Italfarmaco, S.A. | Formulaciones mucoadhesivas semisolidas. |
-
2003
- 2003-07-16 ES ES200301672A patent/ES2237298B1/es not_active Expired - Fee Related
-
2004
- 2004-07-16 SI SI200431522T patent/SI1652535T1/sl unknown
- 2004-07-16 EP EP09161078A patent/EP2100612A3/en not_active Withdrawn
- 2004-07-16 AT AT04742064T patent/ATE482723T1/de active
- 2004-07-16 DK DK04742064.1T patent/DK1652535T3/da active
- 2004-07-16 EP EP04742064A patent/EP1652535B1/en active Active
- 2004-07-16 WO PCT/ES2004/000336 patent/WO2005007194A1/es active Application Filing
- 2004-07-16 US US10/565,062 patent/US8663688B2/en active Active
- 2004-07-16 PT PT04742064T patent/PT1652535E/pt unknown
- 2004-07-16 PL PL04742064T patent/PL1652535T3/pl unknown
- 2004-07-16 DE DE602004029369T patent/DE602004029369D1/de active Active
- 2004-07-16 ES ES04742064T patent/ES2353694T3/es active Active
- 2004-07-16 JP JP2006519939A patent/JP4891765B2/ja active Active
-
2010
- 2010-11-24 HR HR20100635T patent/HRP20100635T1/hr unknown
- 2010-11-25 CY CY20101101079T patent/CY1110954T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2173203T3 (es) * | 1994-10-07 | 2002-10-16 | Columbia Lab Bermuda Ltd | Composicion que comprende una formulacion que actua contra las enfermedades sexualmente transmisibles y su utilizacion. |
WO2001028515A1 (en) * | 1999-10-22 | 2001-04-26 | Líf-Hlaup ehf. Bio-Gels Pharmaceuticals Inc. | Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
WO2003037382A1 (en) * | 2001-10-29 | 2003-05-08 | Columbia Laboratories (Bermuda) Limited | Low concentration of peroxide for treating or preventing vaginal infections |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8663688B2 (en) | 2003-07-16 | 2014-03-04 | Itf Research Pharma, S.L.U. | Semi-solid mucoadhesive formulations |
WO2006138715A1 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company, Inc. | Estrogen compositions for vaginal administration |
WO2006138735A2 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company, Inc. | Gel compositions for topical administration |
WO2006138686A1 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company, Inc. | Estrogen compositions for vaginal administration |
WO2006138735A3 (en) * | 2005-06-16 | 2007-10-25 | Warner Chilcott Co Inc | Gel compositions for topical administration |
US10016442B2 (en) | 2005-06-16 | 2018-07-10 | Allergan Pharmaceuticals International Limited | Estrogen compositions for vaginal administration |
WO2007021805A2 (en) * | 2005-08-12 | 2007-02-22 | Drugtech Corporation | Estrogen compositions and therapeutic methods of use thereof |
WO2007021805A3 (en) * | 2005-08-12 | 2007-08-09 | Drugtech Corp | Estrogen compositions and therapeutic methods of use thereof |
JP2010531302A (ja) * | 2007-06-25 | 2010-09-24 | イタルファルマコ、ソシエダッド、アノニマ | エストリオールの低用量での使用 |
Also Published As
Publication number | Publication date |
---|---|
EP1652535A1 (en) | 2006-05-03 |
DE602004029369D1 (de) | 2010-11-11 |
EP1652535B1 (en) | 2010-09-29 |
US20060240111A1 (en) | 2006-10-26 |
HRP20100635T1 (hr) | 2010-12-31 |
ES2353694T3 (es) | 2011-03-04 |
CY1110954T1 (el) | 2015-06-11 |
JP4891765B2 (ja) | 2012-03-07 |
EP2100612A2 (en) | 2009-09-16 |
SI1652535T1 (sl) | 2010-12-31 |
ATE482723T1 (de) | 2010-10-15 |
ES2237298A1 (es) | 2005-07-16 |
ES2237298B1 (es) | 2006-11-01 |
PL1652535T3 (pl) | 2011-03-31 |
DK1652535T3 (da) | 2010-11-15 |
JP2007528864A (ja) | 2007-10-18 |
PT1652535E (pt) | 2010-11-18 |
US8663688B2 (en) | 2014-03-04 |
EP2100612A3 (en) | 2010-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2237298B1 (es) | Formulaciones mucoadhesivas semisolidas. | |
Woolfson et al. | Drug delivery by the intravaginal route | |
AP691A (en) | Water-based topical cream containing nitroglycerin; method of preparation and use thereof. | |
Vermani et al. | The scope and potential of vaginal drug delivery | |
US7226910B2 (en) | Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists | |
US20050239742A1 (en) | Carrageenan-based formulations and associated methods of use | |
AU2006330846A1 (en) | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | |
MX2008001687A (es) | Composiciones de estrogenos y metodos terapeuticos de uso. | |
AU2005204341A1 (en) | Body cavity foams | |
JP2004535361A (ja) | 生体接着性の徐放性送達独立気泡発泡体フィルム | |
US20110218166A1 (en) | Mucoadherents compositions and their use | |
Bassi et al. | Innovations in bioadhesive vaginal drug delivery system | |
Dobaria et al. | Vaginal drug delivery systems: a review of current status | |
EP1089679B1 (en) | A device and method for the treatment of erectile dysfunction | |
KR20050025166A (ko) | 가온성 및 무자극성 윤활제 항진균성 겔 조성물 | |
Lalan et al. | Polymers in vaginal drug delivery: Recent advancements | |
US7087240B1 (en) | Device and method for the treatment of erectile dysfunction | |
US20040062794A1 (en) | 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy | |
Watkinson | The pharmacokinetics of drug delivery systems in hormone replacement therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006519939 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004742064 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004742064 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006240111 Country of ref document: US Ref document number: 10565062 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10565062 Country of ref document: US |